2/27
06:21 am
maze
Maze Therapeutics, Inc. (NASDAQ: MAZE) was upgraded by analysts at TD Cowen to a "strong-buy" rating.
Low
Report
Maze Therapeutics, Inc. (NASDAQ: MAZE) was upgraded by analysts at TD Cowen to a "strong-buy" rating.
2/26
06:22 am
maze
Maze Therapeutics, Inc. (NASDAQ: MAZE) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Medium
Report
Maze Therapeutics, Inc. (NASDAQ: MAZE) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
2/25
10:32 am
maze
Maze Therapeutics, Inc. (NASDAQ: MAZE) is now covered by analysts at Guggenheim. They set a "buy" rating and a $19.00 price target on the stock.
Medium
Report
Maze Therapeutics, Inc. (NASDAQ: MAZE) is now covered by analysts at Guggenheim. They set a "buy" rating and a $19.00 price target on the stock.
2/25
08:00 am
maze
Maze Therapeutics, Inc. (NASDAQ: MAZE) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $30.00 price target on the stock.
Medium
Report
Maze Therapeutics, Inc. (NASDAQ: MAZE) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $30.00 price target on the stock.
2/25
08:00 am
maze
Maze Therapeutics, Inc. (NASDAQ: MAZE) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $28.00 price target on the stock.
Medium
Report
Maze Therapeutics, Inc. (NASDAQ: MAZE) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $28.00 price target on the stock.
2/7
09:35 am
maze
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease [Yahoo! Finance]
Low
Report
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease [Yahoo! Finance]
2/7
08:00 am
maze
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
High
Report
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
1/30
07:30 pm
maze
Maze Therapeutics Announces Pricing of Upsized Initial Public Offering
Low
Report
Maze Therapeutics Announces Pricing of Upsized Initial Public Offering